Tag: AML

Race Oncology Limited (“Race”) is pleased to provide shareholders with a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene’s commercial partnering and collaboration potential. Key highlights: Read the…

Race Oncology 2022 AGM Presentation by CEO Phil Lynch and CSO Dr Daniel Tillett.

08 June 2022 – Race Oncology Limited (“Race”) is pleased to announce it is expanding the FTO-targeted BISECT (RAC-006) clinical trial in extramedullary Acute Myeloid Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS) to include five additional trial sites in Spain…

Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed using a 4-day treatment of Zantrene in combination with fludarabine and clofarabine Encouraging clinical responses were observed in this very heavily pre-treated AML patient population…

Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO) approval from the Calvary Mater Newcastle Hospital for its open label clinical trial of Zantrene® (bisantrene dihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML)…

6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman ethics approval for its open label clinical trial of Zantrene® (bisantrenedihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or highrisk Myelodysplastic Syndrome (MDS). Before…